晚期三阴性乳腺癌研究进展  

Research Progress in Advanced Triple Negative Breast Cancer

作　　者：吴晓龙 张奇[1] 张伟[1] 张瑞锋 刘林林[1] Wu Xiaolong;Zhang Qi;Zhang Wei;Zhang Ruifeng;Liu Linlin(The Second Hospital of Jilin University,Changchun 130041,China)

机构地区：[1]吉林大学第二医院,长春130041

出　　处：《国际老年医学杂志》2020年第3期197-200,F0003,共5页International Journal of Geriatrics

摘　　要：三阴性乳腺癌(TNBC)是一类复杂的、异质性的乳腺癌亚型,雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2)受体阴性。TNBC具有特殊的生物学行为,侵袭性强,而且在手术、化疗和/或放疗后,早期复发的风险更高,伴有内脏转移。由于缺乏内分泌及HER-2靶向治疗的靶点,目前晚期TNBC的治疗手段主要依靠化疗,但往往持续时间较短,预后较差。因此,迫切需要新的治疗手段。本文就近几年晚期TNBC在化疗、靶向治疗、内分泌治疗和免疫治疗领域最新的进展进行综述。Triple negative breast cancer(TNBC)is a complex and heterogeneous subtype of breast cancer which lacks estrogen receptors,progesterone receptors and human epidermal growth receptor 2(HER-2)receptor.TNBC possesses a special biological behavior and strong aggressiveness.It is associated with a high risk of early relapse with visceral metastasis after surgery,chemotherapy and/or radiotherapy.Due to the lack of therapeutic targets related to endocrine and HER-2,the current treatment of advanced TNBC relies mainly on chemotherapy,but the efficacy is limited and prognosis is poor.Therefore,new therapies are urgently needed.This article reviews the latest advances in chemotherapy,targeted therapy,endocrine therapy and immunotherapy for advanced TNBC.

关 键 词：三阴性乳腺癌 晚期 化疗 靶向治疗 内分泌治疗 免疫治疗 

分 类 号：R737.9[医药卫生—肿瘤]